Gene
ARAF
ARAF is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (1), Actionable biomarkers (3), Trial mentions (14), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention ARAF. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 2 of 8,597 | 0.02% | not measured | |
| 2023 | 2 of 8,275 | 0.02% | 5 of 11,460 | 0.04% |
| 2022 | 0 of 8,285 | 0.00% | 1 of 13,598 | 0.01% |
| 2021 | 0 of 8,692 | 0.00% | 6 of 15,045 | 0.04% |
| 2020 | 2 of 7,640 | 0.03% | 8 of 14,459 | 0.06% |
| 2019 | 0 of 7,300 | 0.00% | 5 of 12,159 | 0.04% |
| 2018 | 0 of 6,927 | 0.00% | 3 of 11,854 | 0.03% |
| 2017 | 2 of 6,558 | 0.03% | 5 of 11,595 | 0.04% |
Showing 10 of 37 years.
Assay-provider ledger (1)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Foundation Medicine | Diagnostic provider | No clinical or analytical validation recorded for this pair | 1 | April 01, 2015 |
Actionable biomarkers (3)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| ARAF oncogenic mutation | Braf Inhibitor + Egfr Mab Inhibitors | responsive | colorectal adenocarcinoma | Cancer Genome Interpreter |
| ARAF oncogenic mutation | Braf Inhibitor + Mek Inhibitors | responsive | colorectal adenocarcinoma | Cancer Genome Interpreter |
| ARAF (S214C) | Sorafenib | response-associated | lung adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (14)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05997602 | Trial eligibility (AACT) |
| NCT06104488 | Trial eligibility (AACT) |
| NCT06411821 | Trial eligibility (AACT) |
| NCT02943031 | Trial eligibility (AACT) |
| NCT06208124 | Trial eligibility (AACT) |
Showing 5 of 14 trial mentions.
Target-disease associations (210)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 6-pyruvoyl-tetrahydropterin synthase deficiency | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Adenoid Cystic Breast Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Adult-onset dystonia-parkinsonism | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Appendix Adenocarcinoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 210 associations.
Vendor sourcing (33)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1509G>A (p.M503I) alteration is located in exon 14 (coding exon 13) of the ARAF gene. This alteration results from a G to A substitution at nucleotide ... | View ClinVar record SCV003581863.2 |
| BioMed Valley Discoveries, Inc | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Histologically confirmed histiocytic neoplasm or histologic findings consistent with histiocytic neoplasm with confirmatory radiologic or molecular find... | View trial NCT06411821 |
| BioMed Valley Discoveries, Inc | Trial collaborator | Mentioned in trial textTrial free-text mention | ARAF | View trial NCT06411821 |
| BioTissue Holdings, Inc | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Subjects with known intolerance to PKS or known allergy to its preservative media. 2. Subjects with symblepharon or lid abnormality preventing PKS plac... | View trial NCT02766907 |
| BioTissue Holdings, Inc | Trial sponsor | Mentioned in trial textTrial free-text mention | PKS | View trial NCT02766907 |
Showing 5 of 33 sourcing records.
Trial-cited literature (56)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Vascular malformations: An overview of their molecular pathways, detection of mutational profiles and subsequent targets for drug therapy. | Frontiers in neurology | 2023 | 18 |
| Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial. | Cell reports. Medicine | 2023 | 16 |
| Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors. | Cancer | 2023 | 9 |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell reports. Medicine | 2023 | 8 |
| A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850. | Oncotarget | 2023 | 8 |
Showing 5 of 56 papers.
Protein variant mentions (10)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.E427K | 1 | 2020 | PMID 33680981 |
| p.F46Y | 1 | 2020 | PMID 33680981 |
| p.G54R | 1 | 2020 | PMID 33680981 |
| p.L98H | 1 | 2020 | PMID 33680981 |
| p.M172V | 1 | 2020 | PMID 33680981 |
Showing 5 of 10 variants.
Literature-extracted relations (2)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Histiocytosis, Langerhans-Cell | Disease | associate |
Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020. | 2021 |
| Histiocytosis, Sinus | Disease | associate |
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. | 2018 |
Organizations publishing (107)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 7 | 2010 to 2019 |
| Dana-Farber Cancer Institute | Other | 5 | 2014 to 2023 |
| Chinese Academy of Medical Sciences & Peking Union Medical College | Academic | 3 | 2017 to 2023 |
| Government of the United States of America | Government | 3 | 2009 to 2023 |
| Harris Health System | Hospital | 2 | 2014 to 2018 |
Showing 5 of 107 organizations.
Where ARAF appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- nervous system disease
- phenotype
201 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.